Objective: To compare high and low starting dose of oxytocin infusion for effectiveness and safety in augmentation of labour in nulliparous women. Results: Of the 258 women enrolled, 133 were randomized to the low and 125 to the high starting oxytocin dose groups. The groups were comparable for maternal and gestational age. There was no difference in mean cervical dilatation before augmentation of labour; six cm in both groups (p=0.167). The mean augmentation to delivery interval was shorter in the high dose group, 218 versus 326 minutes (p< 0.001). There was no difference in the mode of delivery and fetal outcome in terms of birthweight, five minute Apgar score, admission to neonatal unit and perinatal death.
Introduction
Uterine activity is central to the process of parturition, inadequate uterine activity leads to dysfunctional labour usually presenting as prolonged first stage of labour. Oxytocin will induce effective uterine activity when spontaneous uterine contractions are inadequate and the progress of labour is slow.
There is a wide variation in the use of oxytocin especially with regards to the initial starting dose, dose increments, the dosing interval and the maximum allowable dose. 13 Oxytocin has a high therapeutic index where broad ranges of infusion rates and concentrations seem to be both safe and effective.4'5 Over-dosage of oxytocin may lead to hyperstimulation of the uterus leading to foetal hypoxia and even uterine rupture while a sub-optimal dose may lead to failure to progress resulting in unnecessary interventions.4 (' '7 In our hospital, augmentation with oxytocin commenced at a dose of lmIU/min in parous and 4mIU/min in nulliparous women. In most women, a higher oxytocin concentration was required and therefore this regimen was associated with use of large volumes of intravenous fluids. Oxytocin has antidiuretic effects and if infused with a large volume of fluid, there is a risk of fluid overload.' Administering oxytocin with the smallest volume of fluid possible has the advantage of saving on intravenous fluids in addition to reduced risk of fluid overload.
We therefore conducted this study to compare the effectiveness and safety of a high starting dose of oxytocin to the low starting dose regimen that was in place as part of active management of labour in nulliparous women, undergoing augmentation of labour at Harare Maternity Hospital.
Materials and Methods
The study was conducted from May 1907 to January 1998 at Harare Maternity Hospital, a tertiary level hospital with 15 000 deliveries per year. This was an open randomised controlled clinical trial comparing the high to low starting dose oxytocin regimens for augmentation of labour. The non-blinding was due to the different doses of oxytocin and increment intervals used.
Approval for the study was obtained from the institutional review board. Written consent was obtained from the women prior to randomization. Participants were recruited from nulliparous women, with spontaneous onset of labour, referred to Harare Maternity Hospital for delivery. Inclusion criteria w'ere singleton pregnancy, cephalic presentation, gestational age of 36 w'ecks or more with normal foetal heart rate pattern.
A table of random numbers was used to allocate patients into either the low or high starting dose oxytocin group. The allocated group was recorded on a card that was placed in an opaque envelope which was sealed. The envelopes were serially numbered and allocation to a treatment group was through opening the next envelope in the series.
Intervention Groups.
Low starting dose o f oxytocin: This was the regimen in use at our hospital at the beginning of the study. The starting dose for augmentation of labour in nulliparous women was 4mIU/minute. Oxytocin 4mIU was added to a litre of normal saline and infused at a rate lml/min (equivalent to 4mIU/min). For the study, the infusion rate was doubled every 30 minutes as opposed to the 15 minutes interval that was traditionally used. The infusion rate was increased until the patient had three strong contractions in 10 minutes each lasting at least 40 seconds. The infusion rate was then maintained until delivery. If uterine contractions were still poor after achieving the maximum dose of 16mIU/min with the first oxytocin solution (4mIU/ml), a higher concentration (16IU oxytocin in a litre of normal saline) was then used and this gave a maximum dose of 64 mlU/min.
High starting dose o f oxytocin: 10 units of oxytocin in a litre of normal saline were infused starting at a dose of 10 mlU/min (lml/min). The infusion rate was doubled every 60 minutes until the patient had three strong contractions, each lasting at least 40 seconds in a period of 10 minutes.
The high dose oxytocin regimen involved a higher starting dose of lOrnlU per minute compared to 4mIU per minute in the traditional regimen. However, the maximum infusion dose of 40mIU per minute in the new regimen was lower than the maximum dose of 64mIU in the traditional regimen.
In Table I we show the oxytocin concentration and infusion rates for the two regimens. A fluid administration set calibrated such that 15 drops yielded lml fluid was used. The infusion rate was regulated by the nurse-midwife attending to the patient in labour. Tachysystole was defined as more than five contractions occurring in each period of 10 minutes and a hypertonic uterine contraction as one lasting for more than 90 seconds. In the event of tachysystole or hypertonic contraction the oxytocin infusion was stopped and later adjusted to half of the previous dose, if there was no foetal distress on clinical assessment and augmentation was still needed.
Hyperstimulation was defined as tachysystole associated with a foetal heart rate irregularity and was managed by
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Foetal heart rate was monitored by direct auscultation every 30 minutes by the attending nurse-midwife. The decision to perform Caesarean section or operative vaginal delivery was made by the obstetric team on labour ward duty.
The standard partograph was used for monitoring labour progress. Augmentation of labour was part of the active management of labour practised at Harare Maternity Hospital. Augmentation continued for six hours and unless safe delivery was imminent within a further two hours, a Caesarean section was then performed. Caesarean section was also performed for other intrapartum problems. Outcome Measures.
The outcomes assessed included mode of delivery, augmentation to delivery interval, neonatal condition as based on the Apgar score at five minutes and maternal complications.
Results
A total of 258 patients were recruited in the study with 133 and 125 randomised to the low and high oxytocin starting dose groups respectively. There was no difference in mean maternal age, gestational age and cervical dilatation (Table  II) . The proportions of women draining meconium stained liquor at the commencement of augmentation were similar, 27.1% versus 20.0% in the low and high oxytocin dose groups respectively (p=0.232). M e a n a g e (S D ) y e a rs 2 0 .4 (3 .5 ) 2 0 .2 (3 .3 )
M e a n g e s ta tio n a l a g e d (S D ) w e e k s 3 9 .7 (2 .1 ) 3 9 .2 (2 .1 ) M e a n c e rv ic a l d ila ta tio n (S D ) cm 6 , 3 ( 1 7 ) 6.0 ( 1 .6 )
Colour of Amniotlc Fluid
C le a r 9 7 (7 2 ,9 % ) The two groups were similar in terms of mode of delivery although there was a trend towards reduced operative delivery in the high starting oxytocin dose group. There was no difference in the proportion of Caesarean sections performed for foetal distress and for 'failure to progress'. The mean duration of augmentation was shorter in the high starting oxytocin dose group, 218 versus 326 minutes (p<0.001).
There were no differences in foetal outcome in terms of birthweight, (3 065 and 3 010 grams), five minute Apgar score below six (3/129 versus 5/123; p=0.669) and admission to neonatal unit (24/129 versus 26/123; p=0.728) for the low and high starting dose group respectively (Table IV) . The main reason for neonatal unit admission was 'Low Apgar score' although only eight babies were classified as having a five minute Apgar score below six. The perinatal mortality rates were 52.6/1000 and 32/1000 for the low and high dose groups respectively (p=0.610). 
Table IV: Foetal outcome by intervention group. Relative risk (RR) with 95% confidence intervals (Cl).

Intervention Group
Discussion
Failure to progress in labour is one of the common indications for primary Caesarean section in nulliparous women. This is usually due to inefficient uterine action. The use of oxytocin as part of active management of labour is the only alternative to caesarean section in these women.1*' 1 ' Our study has shown that the use of a regimen with a high starting dose of oxytocin and doubling the dose at a 60 minute interval was effective and safe for labour Cent Afr J Med 2001 ;47 ( 11 / 12) augmentation in nulliparous women. These results are consistent with previous studies that used a high dose of oxytocin.g'11 Augmentation with the lowest dose of oxytocin possible has been advocated by others. 13' 512 We used dose incremental intervals of 30 and 60 minutes in the low and high starting doses respectively although the practice in our hospital was a 15 minute incremental interval. Our results, showing that both the 30 and 60 minute incremental intervals were effective, are in agreement with previous reports.210
Longer incremental intervals have been associated with reduction in the maximum dose of oxytocin used, lower episodes of hyperstimulation and foetal distress.213
The longer incremental interval did not increase the duration of labour and may be associated with a decrease in uterine hyperstimulation.
Our finding of a shorter duration of augmentation with the higher oxytocin dose was similar to previous results.1415
One potential problem of high dose oxytocin is uterine hyperstimulation leading to foetal distress or even uterine rupture. 15 We did not detect cases of uterine hyperstimulation. This could be due to the longer intervals (60 minutes) of dose increments in the high oxytocin group or poor monitoring that failed to detect episodes of uterine hyperstimulation. There was no case of uterine rupture.
There was no difference in mode of delivery in our study but use of a high dose of oxytocin has been associated with a reduction in operative delivery.1114 '15 We did not detect a difference in neonatal outcomes. The perinatal mortality rate was similar to that for the hospital. There were more intrapartum deaths in the low starting dose group probably due to undetected hypoxia. There are, however, reports suggesting that use of high dose oxytocin was not associated with increased risk of foetal hypoxia.710
Conclusion
Our results indicate that the regimen starting at oxytocin lOmIU/min was superior to that with a low starting dose of oxytocin 4mIU/min for augmentation of labour in nulliparous women resulting in a shorter duration of augmentation. The shorter augmentation time is of benefit for a busy maternity unit with a limited number of delivery beds. We, therefore, recommend the adoption of oxytocin lOmIU/min as the starting dose for augmentation of labour.
